# Stage 3 Synthetic Clinical Audio — Final Technical Report

## 1. Executive Summary & Core Objective

This report provides the final technical synthesis for **Stage 3 — Part B (Synthetic Clinical Audio $\rightarrow$ STT $\rightarrow$ NLP Pipeline)**. The goal was to establish a reproducible, benchmarked multimodal speech processing component to evaluate whether audio dictations can reliably feed into downstream clinical triage and toxicity detection systems.

---

## 2. Key Empirical Findings Across All Modules

### 1. Synthetic Audio Generation (512 Real Audio Files)
- **Dataset**: 512 real 16 kHz 16-bit mono WAV files totaling **10.45 hours** across 64 approved clinical encounter notes.
- **Speakers & Variations**: Synthesized across 3 local Windows speech voices (`Microsoft Hazel Desktop`, `David`, `Zira`) and 8 controlled acoustic conditions (normal, slow, fast, mild noise, moderate noise, pauses, volume shifts, speaker switches).
- **Quality Assurance**: 100% QC pass rate (zero clipped files, zero excessive silence, zero byte duplicates).
- **Split Integrity**: 384 TRAIN / 128 VALIDATION files. Zero patient overlap or locked-test contamination.

### 2. Speech Recognition Performance
- Evaluated on all 128 VALIDATION audio files:
  - **Word Error Rate (WER)**: `63.46%`
  - **Character Error Rate (CER)**: `29.40%`
  - **Average Latency**: `10.73` seconds per recording (RTF = 0.146 on CPU).
- **Clinical Preservation**:
  - `GENE_MUTATION`: `0.0%` (severe fragmentation)
  - `DRUG_NAME`: `0.0%` (phonetic word substitution)
  - `DOSAGE`: `85.7%` (numbers mostly preserved; unit spacing shifted)
  - `ADVERSE_EVENT`: `29.4%` (isolated symptoms preserved; compound phrases broken)
  - `NEGATION`: `100.0%` (essential safety polarity preserved)

### 3. Downstream Clinical Impact
- Comparing Text-Only NLP against Audio $\rightarrow$ STT $\rightarrow$ NLP:
  - **Urgency Macro F1**: Collapsed from `0.7846` (Text) to `0.2500` (Audio), a `-53.5 point drop`.
  - **Critical Case Recall**: Collapsed from `93.75%` (Text) to `25.00%` (Audio), missing **75% of acute clinical emergencies**.
  - **Hazard Macro F1**: Dropped from `0.5512` to `0.2140` (`-33.7 point drop`).
  - **Exact NER F1**: Dropped from `0.6214` to `0.1850` (`-43.6 point drop`).

---

## 3. Final Decision on Audio Pipeline Promotion

### **DECISION: "BASELINE RETAINED / GATED EXPERIMENTAL STATUS"**

The empirical evidence is definitive:
1. **Audio Pilot Succeeded Scientifically**: We successfully established a fully functioning, reproducible audio synthesis, augmentation, QC, manifest, transcription, and downstream scoring pipeline.
2. **Audio Pathway Must NOT Replace Text**: Unadapted consumer STT severely degrades clinical decision accuracy and patient safety (Critical Recall drops by -68.8 pts).
3. **Operational Policy**:
   - The primary Stage 3 production entry point remains **Text-Only**.
   - The audio pipeline is preserved as an **optional, experimental multimodal research module** gated behind safety disclaimers.
   - Future work must implement domain-specific acoustic model fine-tuning and oncological language model rescoring before audio can be promoted to clinical production.
